Horizon Pharma (HZNP) Tops Q3 EPS by 15c

Horizon Pharma (NASDAQ: HZNP) reported Q3 EPS of $0.65, $0.15 better than the analyst estimate of $0.50. Revenue for the quarter came in at $325.3 million versus the consensus estimate of $311.85 million.

GUIDANCE:

Horizon Pharma sees FY2018 revenue of $1.17-1.2 billion, versus the consensus of $1.18 billion.

the Company increased its full-year 2018 adjusted EBITDA guidance range to $420 million to $430 million, from $400 million to $420 million.

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

You May Also Be Interested In

• Rexford Industrial Realty (REXR) Reports In-Line Q1 EPS, provides guidance
• Equifax (EFX) Tops Q1 EPS by 6c, Misses on Revenue; Offers Guidance
• First Industrial Realty (FR) Tops Q1 EPS by 21c